Healthcare Equipment and Supplies
Company Overview of InnFocus, Inc.
InnFocus, Inc., a biomaterials company, develops and provides products in ophthalmology. The company's product portfolio includes an intraocular lens for microincision surgery and an implantable device for glaucoma. The company was incorporated in 2003 and is based in Miami, Florida.
12415 SouthWest 136 Avenue
Miami, FL 33186
Founded in 2003
Key Executives for InnFocus, Inc.
Chief Executive Officer and President
Founder and Chairman Emeritus
Compensation as of Fiscal Year 2015.
InnFocus, Inc. Key Developments
InnFocus, Inc. Announces Board Appointments
Apr 16 15
InnFocus, Inc. reported Director Randy Lindholm has been named Chairman of the Board. Mr. Lindholm was previously Chairman of the Board and CEO of Vidamed, until it was acquired by Medtronic. He was also Chairman of the Board of Crux Biomedical. Mr. Lindholm currently serves as a Director for publicly held Omnicell. The company also announced Tim Willis, previous President and CEO of TearScience, has joined the Board of Directors, and will head up the Committee for External Financing. He has more than 30 years experience in ophthalmology, having helped seven company startups, and has raised over $120 million in funding. He is a member of the American Society of Cataract and Refractive Surgery, the Association of Research in Vision and Optics, the Licensing Executive Society, and is a Fellow of the American Academy of Optometry.
InnFocus' MicroShunt® Continues to Show Excellent Results
Jan 12 15
InnFocus, Inc. reported the InnFocus MicroShunt has now been used in more than 100 glaucoma surgeries worldwide, in the current configuration and surgical technique, with patients followed for up to three years. Results outside the United States show patients achieve a mean Intra Ocular Pressure (IOP) below 14 mmHg after implantation of the InnFocus MicroShunt which studies show is key for stopping the progression of vision loss in glaucoma sufferers. Patients experience over 80% reduction in their eye drop medication use--and over 70% are off medications completely at 3 years. The InnFocus MicroShunt glaucoma drainage implant, made from the Company's revolutionary SIBS material which has a 13-year proven history in drug eluting coronary stents and 7 years in ophthalmology, is ultra-stable, and will not degrade. The InnFocus MicroShunt consists of a microtube about the twice the size of an eyelash. It is currently in Phase 1 Food and Drug Administration trials at 12 centers in the United States. Patients have also been treated in France, Japan, Netherlands, Spain, Switzerland, and the Dominican Republic. The InnFocus MicroShunt has been implanted alone or in combination with cataract surgery in clinical trials outside the United States. It was developed in collaboration with the University of Miami's Bascom Palmer Eye Institute. It provides a quick and simple method of shunting aqueous humor from the anterior chamber to a diffuse bleb without the use of a scleral flap. It uses a patented micro-shunt made from the innovative SIBS Material to control flow. The mechanism of action for the InnFocus MicroShunt of subconjunctival/Tenons drainage has been the accepted gold standard for decades.
InnFocus, Inc. Presents at 8th Annual OneMedForum 2015, Jan-12-2015
Dec 19 14
InnFocus, Inc. Presents at 8th Annual OneMedForum 2015, Jan-12-2015 . Venue: San Francisco Marriott Marquis, Parc 55 Wyndham, Union Square, San Francisco, California, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|